Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: impact of drug-drug interactions and cigarette …
Tizanidine is an alpha2-adrenergic agonist, used to treat spasticity associated with multiple
sclerosis and spinal injury. Tizanidine is primarily metabolized by CYP1A2 and is …
sclerosis and spinal injury. Tizanidine is primarily metabolized by CYP1A2 and is …
Understanding interindividual variability in the drug interaction of a highly extracted CYP1A2 substrate tizanidine: application of a permeability-limited …
M Zhang, C Fisher, I Gardner, X Pan, P Kilford… - Drug Metabolism and …, 2022 - ASPET
Tizanidine, a centrally acting skeletal muscle relaxant, is predominantly metabolized by
CYP1A2 and undergoes extensive hepatic first-pass metabolism after oral administration. As …
CYP1A2 and undergoes extensive hepatic first-pass metabolism after oral administration. As …
Creation of novel sensitive probe substrate and moderate inhibitor models for a comprehensive prediction of CYP2C8 interactions for tucatinib
IE Templeton, K Rowland‐Yeo… - Clinical …, 2024 - Wiley Online Library
A physiologically‐based pharmacokinetic (PBPK) model was developed to simulate plasma
concentrations of tucatinib (TUKYSA®) after single‐dose or multiple‐dose administration of …
concentrations of tucatinib (TUKYSA®) after single‐dose or multiple‐dose administration of …
Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data
A Nordmark, A Andersson, P Baranczewski… - European journal of …, 2014 - Springer
Purpose Static and dynamic (PBPK) prediction models were applied to estimate the drug–
drug interaction (DDI) risk of AZD2066. The predictions were compared to the results of an in …
drug interaction (DDI) risk of AZD2066. The predictions were compared to the results of an in …
Physiologically based pharmacokinetic modeling to predict complex drug–drug interactions: a case study of AZD2327 and its metabolite, competitive and time …
J Guo, D Zhou, Y Li, BH Khanh - Biopharmaceutics & Drug …, 2015 - Wiley Online Library
{(R)‐(3‐Aminophenyl)[4‐(4‐fluorobenzyl)‐piperazin‐1‐yl] methyl}‐N, N‐diethylbenzamide
(AZD2327) is a highly potent and selective agonist of the δ‐opioid receptor. AZD2327 and N …
(AZD2327) is a highly potent and selective agonist of the δ‐opioid receptor. AZD2327 and N …
A physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug–drug–gene interactions with fluvoxamine …
T Kanacher, A Lindauer, E Mezzalana, I Michon… - Pharmaceutics, 2020 - mdpi.com
Physiologically-based pharmacokinetic (PBPK) modeling is a well-recognized method for
quantitatively predicting the effect of intrinsic/extrinsic factors on drug exposure. However …
quantitatively predicting the effect of intrinsic/extrinsic factors on drug exposure. However …
Comprehensive PBPK model of rifampicin for quantitative prediction of complex drug‐drug interactions: CYP3A/2C9 induction and OATP inhibition effects
R Asaumi, K Toshimoto, Y Tobe… - CPT …, 2018 - Wiley Online Library
This study aimed to construct a physiologically based pharmacokinetic (PBPK) model of
rifampicin that can accurately and quantitatively predict complex drug‐drug interactions …
rifampicin that can accurately and quantitatively predict complex drug‐drug interactions …
Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform …
DJ Mulford, D Ramsden, L Zhang… - CPT …, 2023 - Wiley Online Library
Vonoprazan is metabolized extensively through CYP3A and is an in vitro time‐dependent
inhibitor of CYP3A. A tiered approach was applied to understand the CYP3A victim and …
inhibitor of CYP3A. A tiered approach was applied to understand the CYP3A victim and …
A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated …
S Frechen, J Solodenko, T Wendl… - CPT …, 2021 - Wiley Online Library
The success of applications of physiologically‐based pharmacokinetic (PBPK) modeling in
drug development and drug labeling has triggered regulatory agencies to demand rigorous …
drug development and drug labeling has triggered regulatory agencies to demand rigorous …
Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug–Drug Interactions
P Kilford, N Khoshaein, R Southall… - European Journal of Drug …, 2022 - Springer
Abstract Background and Objectives Index substrates and inhibitors to investigate the role of
the polymorphic enzyme, cytochrome P450 (CYP) 2D6, in the metabolism of new …
the polymorphic enzyme, cytochrome P450 (CYP) 2D6, in the metabolism of new …